Salute e Benessere

ADNOC Gas Delivers Best-Ever Q3 Results, Demonstrating Resilience and Growth in…

Q3 2025 saw ADNOC Gas' domestic gas business deliver record results, with EBITDA rising to $914 million, up 26% year-on-year. The strength of the UAE economy, which the IMF predicted will grow by 4.8% in 2025 and 5% in 2026, was the primary driver of a 4% increase in domestic gas sales volumes for the first nine months. That is coupled with improved underlying margins following successful structural improvements from contract renegotiations. Q3 2025 saw ADNOC Gas' domestic gas business…
PR Newswire
13/11/2025

Large health system in southeast US adopts Sectra's cloud service across 11…

As Sectra One Cloud is a fully managed cloud solution, Sectra will monitor, optimize, and continuously upgrade the solution, alleviating the burden from the healthcare system's IT teams. The solution can also be scaled to accommodate growth as volumes increase and expansion into other imaging specialties. As Sectra One Cloud is a fully managed cloud solution, Sectra will monitor, optimize, and continuously upgrade the solution, alleviating the burden from the healthcare system's IT teams...
PR Newswire
13/11/2025

KHB Showcases the Enhanced FOCUS PEGASUS MF200 -- Redefining Efficiency in…

Smart POCT Solutions for Pet Health Smart POCT Solutions for Pet Health 4-in-1 Integration:Biochemistry, Electrolytes, Coagulation, and Immunofluorescence testing combined in one compact platform. Enables veterinarians to perform multi-type tests on one device. One-Step Operation:Simplified workflow delivers results within10 minutes. Broad Test Menu:Covers over90% of routine pet diagnostics Animal-friendly Design:Requires no more than100 μLof sample, ensuring...
PR Newswire
13/11/2025

IMU Biosciences announces formation of Scientific Advisory Board

PRESS RELEASE Inaugural members are highly distinguished healthcare experts in haematology, vaccinology, immunology and geneticsLondon, UK, 13 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the formation of its Scientific Advisory Board (SAB).Professor Paresh Vyas, Professor Bali Pulendran, Professor Adrian Hayday and Dr Peter Goodfellow, four leading...
Nasdaq GlobeNewswire
13/11/2025

Clarivate Companies to Watch Report Spotlights Seven Women's Health Startups…

Despite representing half the global population, women remain underrepresented in clinical research and healthcare investment, with women's health accounting for just 15% of venture capital and 5% of global healthcare R&D funding. Rediscovering Women's Health highlights organizations addressing these gaps through inclusive research, novel therapies and a deeper understanding of female-specific conditions such as early menopause, polycystic ovary syndrome (PCOS) and endometriosis, factors…
PR Newswire
13/11/2025

Inventiva announces temporary trading halt of its ordinary shares on Euronext…

Daix (France), New York City (New York, United States), November 13, 2025 –Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (" MASH "), announced today that trading of its ordinary shares on the regulated market of Euronext Paris (" Euronext Paris ") will be temporarily…
Nasdaq GlobeNewswire
13/11/2025

Enterome to present positive interim Phase 2 data for lead OncoMimics™…

New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-burden follicular lymphoma in need of treatmentAll six patients responded positively to the combination Overall response data in cohort 2 confirm EO2463 monotherapy produces marked efficacy in patients in watch-and-wait settingRegistrational Phase 3 trial could start in 2026 in the watch-and-wait settingParis, France – 13 NOVEMBER 2025 (08:30 CET)Enterome, a clinical-stage company...
Nasdaq GlobeNewswire
13/11/2025

Interim Report for the period July - September 2025: BioArctic

Events during the third quarter 2025 Events during the third quarter 2025 Events after the end of the third quarter Financial summary July –September 2025 Comments from the CEO "Our collaboration with Novartis marks an exciting new chapter for BioArctic" Our journey into a new era and the work to meet our long-term ambitions continues, with several important milestones reached during the quarter. The progress made underscores our strong commitment to delivering...
PR Newswire
13/11/2025

Bioretec Ltd's business review January-September 2025: Strengthening commercial…

July–September 2025 in brief July–September 2025 in brief January–September 2025 in brief Key figures Key events during July–September 2025 CEOSarah van Hellenberg Hubar-Fisher'scomments: Strengthening commercial foundations and strategy design "Almost six months have passed since I assumed my position as Bioretec's CEO. While I remain very enthusiastic about Bioretec's next phase of growth and the opportunity to lead us there, it has become increasingly evident...
PR Newswire
13/11/2025

THERANEXUS : THX Pharma announces the strong success of its approximately EUR 8…

Capital increase of €7.8 million through the issuance of 4,356,804 new shares at a unit price of €1.80 The transaction received strong support from existing shareholders, whose demand on irreducible and reducible basis, under the preferential subscription rights amounted to 1,742,660 shares Lyon, France – November 13, 2025, 8am CEST – THX Pharma…
Actusnews Wire
13/11/2025

T-Therapeutics announces Series A extension to $91 million to advance…

$32 million new equity injection adds to previously announced $59 millionNew investors Tencent and BGF joined by all existing major shareholdersFunds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease 13 November 2025; Cambridge, England– T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing,...
Nasdaq GlobeNewswire
13/11/2025

Robert Lewandowski Named Global Brand Ambassador for KSM-66 Ashwagandha

The partnership pairs Lewandowski's two-decade career at football's elite level with KSM-66 Ashwagandha's commitment to 4000 year old Ayurvedic tradition of root-only extraction. His consistency across leagues and clubs, from Borussia Dortmund to Bayern Munich to FC Barcelona, mirrors the quality standards that define KSM-66's manufacturing approach. Manufactured by Ixoreal Biomed, KSM-66 Ashwagandha is trusted as a star ingredient in products of over 4,500 brands worldwide. The partnership...
PR Newswire
13/11/2025

Zealand Pharma Announces Financial Results for the First Nine Months of 2025

Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025 With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and survodutide, upcoming Capital Markets Day will set the stage for a catalyst-rich 2026.Achieved key milestone in the petrelintide Phase 2 ZUPREME-1 trial in people with overweight and obesity, with the last participant completing the 28-week primary endpoint visit, paving...
Nasdaq GlobeNewswire
13/11/2025

WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical…

Key Takeaways from the WRN Inhibitors Market Report Key Takeaways from the WRN Inhibitors Market Report Discover which indication is expected to grab the major WRN inhibitors market share @WRN Inhibitors Market Report Key Factors Driving the WRN Inhibitors Market Synthetic Lethality Targeting in MSI Cancers WRN inhibitors exploit synthetic lethality by targeting the Werner syndrome helicase (WRN), critical for DNA repair in MSI-H tumors. Tumors with high microsatellite...
PR Newswire
12/11/2025

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum)…

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate of 97.4% based on estimand method, equating to 99.2% under conventional per protocol analysis If approved, GanLum would represent first major innovation in malaria treatment since 1999, with potential to kill drug-resistant parasites and block transmissionNovel ingredient in...
Nasdaq GlobeNewswire
12/11/2025

Alvotech Reports Results for the First Nine Months of 2025 and Provides a…

Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same period last yearLicense and other revenue decreased by 13% to $182 million, compared to the same period last yearAdjusted EBITDA in the first nine months of the year was $68 million, a 21% decrease from the same period last year, driven by higher R&D...
Nasdaq GlobeNewswire
12/11/2025

Essity acquires Edgewell's feminine care business in North America including the…

"I´m looking forward to further grow these well-known brands, using our established recipe for success within Feminine Care. With this acquisition we are building a stronger personal care business in North America, in line with our strategy to focus on high yielding categories in attractive geographies." says Ulrika Kolsrud, President and CEO of Essity. "I´m looking forward to further grow these well-known brands, using our established recipe for success within Feminine Care. With…
PR Newswire
12/11/2025

Inventiva announces launch of public offering

Daix (France), New York City (New York, United States), November 12, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (" MASH "), today announced that it plans to offer and sell approximatively $125 million (representing approximately €108 million) of new American Depositary…
Nasdaq GlobeNewswire
12/11/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from November 03rd to November 07th 2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1103/11/2025FR0010259150300...
Nasdaq GlobeNewswire
12/11/2025

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of October 31, 2025(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (November 12, 2025 - 6:00 pm)– As of October 31, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down...
Nasdaq GlobeNewswire
12/11/2025

IBA – TRANSPARENCY NOTIFICATION

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)Louvain-la-Neuve, Belgium, November 12 th, 2025 06:00 PM Summary of the notificationIBA SA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the...
Nasdaq GlobeNewswire
12/11/2025

MHRA Approves BetaGlue Therapeutics’ Clinical Trial Application for YntraDose™…

®Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has approved the Clinical Trial Application for YntraDose™ in unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma (LA-PDAC).The clinical study is an early feasibility clinical investigation and will...
Nasdaq GlobeNewswire
12/11/2025

Wandercraft and SAPA Announce Deployment Partnership in Industrial…

PARIS and ARPAIA, Italy, Nov.12, 2025(GLOBE NEWSWIRE) -- Wandercraft, a global leader in autonomous robotics, and SAPA, Italy-based ‘One-Shot Company’ and Tier 1 supplier renowned for its innovative approach to automotive parts manufacturing, today announced a Deployment Partnership to implement and scale deployment of Calvin-40, Wandercraft’s autonomous heavy-payload, modular humanoid robot, in SAPA’s industrial operations.This milestone builds on Wandercraft’s Strategic Partnership...
Nasdaq GlobeNewswire
12/11/2025

Head and Neck Cancer Drugs/Therapeutics Market Backed by Growing Adoption of…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=219003 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=219003 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Head and Neck Cancer Drugs/Therapeutics Market Overview 1. Rising Global Incidence and Growing Patient Population The Head and Neck Cancer Drugs/Therapeutics Market is significantly influenced by the increasing global incidence...
PR Newswire
12/11/2025
Altri  Comunicati